Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, August 2008, p. 1188-1193, Vol. 15, No. 8
1071-412X/08/$08.00+0 doi:10.1128/CVI.00478-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
,
Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, Bilthoven, The Netherlands,1 Department of Immunology, University Medical Center, Utrecht, The Netherlands,2 Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands,3 Laboratory of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands4
Received 6 December 2007/ Returned for modification 8 February 2008/ Accepted 3 June 2008
|
|
|---|
0.85) for each of the subclasses. We conclude that the hexaplex meningococcal subclass MIA is an easy and specific assay for the determination of anti-MenA and anti-MenC PS subclass IgG, requiring minimal amounts of serum to study IgG subclass responses to vaccines. |
|
|---|
IgG antibodies directed at the PS capsules of bacteria like Neisseria meningitidis are protective against invasive disease. In order to increase the immunogenicity of PS as vaccines, protein carriers are covalently coupled to PS. This changes the original TI response to a T-cell-dependent response (3, 13, 14). This may result in a decrease in the IgG2/IgG1 ratio, as shown previously for pneumococcal-conjugate vaccines in children and adults (6, 25). Nevertheless, the IgG2/IgG1 ratio may be crucial for monitoring after-vaccination and long-term immunity since the subclasses may have different protective properties.
Conventional methods for detection of IgG and the IgG subclasses are based on enzyme-linked immunosorbent assays (ELISA) (2, 7, 12). ELISA is a reproducible and specific assay but time-consuming and often limited by the amount of available serum, particularly when multiple analytes need to be tested. Newly developed methods, such as fluorescent particle-based multiplex flow cytometric immunoassays (MIA), using fluorescent distinct beads as a carrier for different antigens enable the detection of multiple analytes in a single sample (1, 15, 16, 18, 19, 20, 23, 26) with limited amounts of serum.
Unfortunately, existing MIA systems are not able to detect different subclasses of IgG to multiple antigens in a single well. Therefore, we designed a meningococcal subclass MIA according to the same principles as those of the method of Prince et al. (23). A MIA was developed in order to measure IgG and the IgG1 and IgG2 subclass responses to meningococcal serogroup A (MenA) and C (MenC) PS and subsequently to study immune responses to meningococcal PS and PS-conjugate vaccines.
|
|
|---|
Coupling of MenA and MenC PS to carboxylated fluorescent beads. N. meningitidis serogroup A and serogroup C capsular PS (National Institute for Biological Standards and Control [NIBSC], Potters Bar, United Kingdom) were conjugated to poly-L-lysine (Sigma-Aldrich, St. Louis, MO) as described previously (10, 15). This conjugate was covalently attached to fluorescent carboxylated beads (Bio-Rad Laboratories, Hercules, CA) using a two-step carbodiimide reaction (15, 27).
MIA for the quantification of MenA and MenC PS antibodies. The MenA and -C PS subclass MIA was performed as described previously (15) with modifications. Reference serum sample CDC1992 (NIBSC code 99/706) was serially diluted in phosphate-buffered saline (PBS), pH 7.2, containing 50% antibody-depleted human serum (Valley Biomedical, Winchester, VA); unknown and control serum samples (control serum 89S-2 [FDA, Frederick, MD] and in-house control serum obtained from Wyeth, Collegeville, PA) were diluted 1:100 in the same buffer. Previously assigned concentrations of meningococcal IgG, IgG1, and IgG2 antibodies in CDC1992 were used in this assay (11, 12). Standard and serum samples were added to an equal volume of MenA- and -C-conjugated beads (4,000 beads/antigen/well) in a 96-well MV Multiscreen filter plate (Millipore, MA) and incubated for 20 min at room temperature (RT) on a plate shaker at 650 rpm in the dark. After three washes with PBS using a vacuum manifold, wells containing beads for determination of IgG received R-phycoerythrin-conjugated goat anti-human IgG (gamma chain specific) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) diluted 1:200 in PBS. Wells for detection of IgG1 and IgG2 received a mouse anti-human monoclonal antibody solution for detection of human IgG1 (clone HP6069; dilution, 1:100) and IgG2 (clone HP6002; dilution, 1:200) (Zymed Laboratories, Invitrogen, Paisley, United Kingdom), respectively, both diluted in sample buffer. After another incubation of 20 min at RT on a plate shaker in the dark and three washes, wells for detection of the IgG subclasses received R-phycoerythrin-conjugated goat anti-mouse IgG (gamma chain specific) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) diluted 1:200 in PBS and wells for detection of IgG on the same plate received PBS. After a 20-min incubation in the dark at RT on a plate shaker and three washes, each duplex of a given sample was suspended in PBS and carefully mixed with the other duplexes. Samples were analyzed as a hexaplex using a Bio-Plex system in combination with the Bio-Plex Manager software, version 4.1.1 (Bio-Rad Laboratories, Hercules, CA). For each analyte, mean fluorescent intensity (MFI) was converted to µg/ml by interpolation from a five-parameter logistic standard curve.
Assay specificity. The MenA and -C PS-specific IgG, IgG1, and IgG2 specificities were determined as described previously (15), with the modification that different serum specimens were tested: CDC1992, 89S-2, and an in-house reference serum.
Assay sensitivity. To determine the sensitivity of the subclass MIA, we used a method described previously (15) with the exception that 40 blank wells were used. The means plus 2 standard deviations were calculated, and minimal levels of detection (MLD) were determined. The lower limit of quantitation (LLOQ) was calculated as three times the MFI of the MLD (5).
Assay reproducibility. The reproducibility of the meningococcal subclass MIA was determined by measuring intra-assay variation and interassay variation. Intra-assay reproducibility was calculated as the mean percentage of coefficients of variation (CVs) for 10 samples determined in duplicate within one plate. The interassay variation was assessed by testing samples (n = 54) in duplicate on two different days, and the CV percentages were calculated.
ELISA for determination of meningococcal serogroup A and C PS IgG1 and IgG2 antibodies. MenA- and -C-specific IgG, IgG1, and IgG2 ELISA were performed as described previously (2, 7, 12), with the modification that different secondary conjugated antibodies were used: a goat anti-human IgG alkaline phosphatase-labeled antibody (Biosource, Camarillo, CA) and a rabbit anti-mouse Ig horseradish peroxidase-labeled antibody (DAKO, Glostrup, Denmark).
|
|
|---|
(ii) Standard curves. Previously assigned antimeningococcal IgG, IgG1, and IgG2 concentrations for reference serum CDC1992 where used. As shown earlier (15), the standard curves for detection of MenA and -C IgG showed a good linearity over six fourfold dilutions of the reference serum. Standard curves for MenA and -C IgG1 showed good linearity over four steps of a fourfold dilution of the reference serum and were also parallel with the corresponding IgG line according to the principles of Plikaytis et al. (21). The same result was found for the IgG2 subclass of MenA and -C antibodies in five steps of a fourfold dilution of the reference serum.
Assay validation. (i) Specificity. The specificity of the meningococcal subclass MIA was assessed by preabsorption with free PS. Good specificity was observed for MenA and -C in serum samples CDC1992 and 89S-2 and an in-house reference serum. The percent reductions of MFIs after homologous serogroup PS was added exceeded 85%, 75%, and 80% for IgG, IgG1, and IgG2, respectively, for both serogroups. Addition of heterologous PS resulted in inhibition of less than 20% (IgG), <25% (IgG1), and <10% (IgG2) for both serogroups.
(ii) Sensitivity. For the determination of the sensitivity of the meningococcal subclass MIA, values obtained from blank wells were compared to the relevant standard curve (Table 1). The LLOQ for detection of anti-MenC IgG in the subclass MIA is approximately 50 times more sensitive than that for detection of anti-MenC IgG in the ELISA (data not shown).
|
View this table: [in a new window] |
TABLE 1. Calculated MLD and LLOQ for each of the individual IgG subclasses
|
|
View this table: [in a new window] |
TABLE 2. Interassay variability for detecting antimeningococcal IgG subclass responses using ELISA and MIA
|
![]() View larger version (30K): [in a new window] |
FIG. 1. Comparison of IgG, IgG1, IgG2, and sums of IgG1 and IgG2 obtained by the meningococcal serogroup A ELISA and MIA. (A) Comparison of IgG between ELISA and MIA. (B) Comparison of the sum of IgG1 and IgG2 with IgG obtained by MIA. (C) Comparison of the sum of IgG1 and IgG2 with IgG obtained by ELISA. (D) Comparison of IgG1 between ELISA and MIA. (E) Comparison of IgG2 between ELISA and MIA. (F) Comparison of the sum of IgG1 and IgG2 between ELISA and MIA.
|
![]() View larger version (29K): [in a new window] |
FIG. 2. Comparison of IgG, IgG1, IgG2, and sums of IgG1 and IgG2 obtained by the meningococcal serogroup C ELISA and MIA. (A) Comparison of IgG between ELISA and MIA. (B) Comparison of the sum of IgG1 and IgG2 with IgG obtained by MIA. (C) Comparison of the sum of IgG1 and IgG2 with IgG obtained by ELISA. (D) Comparison of IgG1 between ELISA and MIA. (E) Comparison of IgG2 between ELISA and MIA. (F) Comparison of the sum of IgG1 and IgG2 between ELISA and MIA.
|
|
|
|---|
Previously described MIA all use different buffers as serum diluents. The buffers described are PBS with various concentrations of Tween 20 (16, 19, 20), fetal calf serum (15, 18), bovine serum albumin (1, 23, 26), or antibody-depleted human serum (1, 4). We found that antibody-depleted human serum at a concentration of 50% in PBS could substantially reduce nonspecific signals in comparison with buffers containing fetal calf serum or Tween 20 (see the figure in the supplemental material). By using antibody-depleted human serum, no nonlinearity between samples and reference serum was detected; therefore, one serum dilution was sufficient for the determination of specific antibodies.
No interference or cross-reactivity between different duplex assays was observed, indicating that antigen-antibody complexes were stable, which is comparable to results from Prince et al. (23). In addition, combining the duplex assays to form a hexaplex MIA ensures identical measuring conditions and reduces the analysis time by at least a factor of 2. The linearity and range of standard curves for MenA and -C IgG are similar to the results of Lal et al. (15). These were found to be lower for the individual IgG subclasses, possibly due to lower levels of subclass antibodies present in reference serum CDC1992. The specificity of the MIA for the detection of IgG and IgG subclasses for MenA and -C was found to be comparable to those of other MIA (1, 15, 16).
Intra- and interassay variation revealed the good reproducibility of the assay. The MIA proved to be more reproducible than ELISA, with low day-to-day variation. Daily variation is higher for the IgG subclass concentrations than for IgG because IgG subclass concentrations can be very low; therefore, higher variations between days will be found. Moreover, more variation is also introduced in the subclass MIA by the use of mouse monoclonal antibodies for the detection of the IgG subclasses.
IgG and IgG subclass concentrations determined by the meningococcal subclass MIA showed a good correlation with those from individual ELISA for the same antigens. The number of serum samples tested is comparable to those from other studies (15, 19, 26), and the samples span a wide range in concentrations for all types of IgG. The levels of MenA IgG1 antibodies in sera with low titers (<1 µg/ml) in the meningococcal subclass MIA were in general higher than those in ELISA. It is unclear why this dissimilarity between the two assays occurs, especially because anti-MenA IgG2 and anti-MenC IgG1 and IgG2 antibody levels in sera with low IgG subclass concentrations (<1 µg/ml) were in general lower in the meningococcal subclass MIA than in ELISA (Fig. 1E and 2D and E). This indicates that less nonspecific signal is observed when IgG subclass concentrations are determined with the meningococcal subclass MIA, with the exception of IgG1 for MenA. These discrepancies in serum samples with an anti-PS IgG concentration of less than 1 µg/ml were also observed by Lal et al. (15) and Pickering et al. (20) for several other bacterial PS capsules.
A major advantage of the meningococcal subclass MIA described here in comparison with the ELISA is that substantially less volume of the specimens is needed for the assay. The MIA requires 5 µl of serum, while at least 60 µl is needed for ELISA. Besides the reduction of specimen volume, shorter incubation periods and incubation at RT are benefits. Furthermore, the use of antigen and reagents is extremely reduced. The amount of antigen needed to determine IgG, IgG1, and IgG2 in a single serum sample using the meningococcal subclass MIA is up to 65-fold less than for ELISA. Additionally, due to the flexibility of the system the assay can be extended in time without increasing specimen volume or assay time (100 different bead regions are available, and systems that can measure up to 500 analytes in a single well are under construction). For instance, the assay was expanded for the subclass responses to meningococcal serogroups W-135 and Y. By adding beads conjugated with MenY and MenW-135 PSs to the three different duplex assays, IgG, IgG1, and IgG2 responses to these PSs could be measured simultaneously. R2 correlations between IgG and the sum of IgG1 and IgG2 for W-135 and Y PS were at least 0.90 (data not shown).
In conclusion, our results indicate that the meningococcal subclass MIA described here is an assay in which the IgG subclass responses to MenA and MenC PS can be easily and specifically measured. There is a good correlation between the meningococcal subclass MIA and in-house ELISA for the detection of IgG subclasses. The meningococcal subclass MIA is an excellent alternative to existing ELISA, which would simplify and speed up the evaluation of the immunogenicity of meningococcal PS and conjugate vaccines.
Published ahead of print on 11 June 2008. ![]()
Supplemental material for this article may be found at http://cvi.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»